Highlights
- 1
- 2JAMA internal medicine · 2022
- 3Harm reduction journal · 2021
Publications
68 publications
Funding
19 grantsView NIH portfolio on RePORTER ↗
Active
7 grants- KPP30AI191337-01A1Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
- Co-IT32AI007613-26A1Research Training in Infectious DiseasesNational Institute of Allergy and Infectious Diseases · 2020–2030· 2 renewals
- Co-IR01AG081155-03Hormone Therapy for Peri- and Postmenopausal Women with HIV (HoT): ACTG A5424National Institute on Aging · 2025–2028 · via University of North Carolina at Chapel Hill
- MPIUM1AI068636-20ACTG Leadership and Operations Center (LOC) - CRS 7804National Institute of Allergy and Infectious Diseases · 2012–2027 · via University of North Carolina at Chapel Hill· 9 renewals
- KPUM1AI069419-15Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitNational Institute of Allergy and Infectious Diseases · 2013–2027· 2 renewals
- Sub-PIR01HL156788-05The Role of Sleep in Cardiovascular Health Among Men Living With HIVNational Heart, Lung, and Blood Institute · 2024–2027 · via Rutgers, The State University of New Jersey – New Brunswick
- Co-IUM1AI068619-19HIV Prevention Trials Network (HPTN106 FHI360 - WCM)National Institute of Allergy and Infectious Diseases · 2020–2026 · via FHI 360· 2 renewals
Completed grants (12)
- MPIR01HL149516-01A1ACTG LOC (A5415 FDG PET/CT Scans)National Heart, Lung, and Blood Institute · 2023–2024 · via University of California, Los Angeles
- MPIUG3HL164285-011/2 REPRIEVE Extension for Trial CompletionNational Heart, Lung, and Blood Institute · 2023–2024 · via The General Hospital Corporation (dba Massachusetts General Hospital)
- Sub-PIFHI 210569-01CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.)National Institute of Allergy and Infectious Diseases · 2020–2023 · via FHI 360
- Sub-PI5 UM1 AI068619615CoVPN 3004: Phase 3, SARS-CoV-2 Vaccine (Novavax)National Institute of Allergy and Infectious Diseases · 2020–2023 · via FHI 360
- MPIR01AG054366-05Pitavastatin to Reduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: 1560 B WB699National Institute on Aging · 2018–2023 · via University of California, Los Angeles
- MPIU01HL123336-01A5332: Prevention of Vascular Events in HIV - REPRIEVE & Substudy A5333s: Pitavastatin on CAD & Inflammatory BiomarkersNational Heart, Lung, and Blood Institute · 2014–2023 · via The Brigham & Women's Hospital INC
- MPIR01DK108438-05Effect of Pitavastatin on Kidney Function in HIV-infected Persons - CRS 7804 1560 B XA868National Institute of Diabetes and Digestive and Kidney Diseases · 2018–2022 · via University of California, Los Angeles
- Sub-PIR01DA041298-04Accessible Care Intervention for Engaging People who Inject Illicit Drugs (PWID) in Hepatitis C CareNational Institute on Drug Abuse · 2016–2021 · via Research Foundation of CUNY· 2 renewals
- KP5 U1O HA29291-02AIDS Education and Training Centers Program (AETC)Health Resources and Services Administration · 2015–2019 · via Columbia University
- PIBMS AI444-385Rates of Mixed Hepatitis C Infection in Active Injection Drug Users and the Impact of Low Level Mixed Infection on Treatment OutcomesBristol-Myers Squibb · 2015–2018
- PIK23AI065319-05Thrombocytopenia & HIV/HCV: Risk Factors & TreatmentNIAID · 2005–2010 · via NIH RePORTER
- MPIM01RR000047-47SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCVNCRR · 2005–2007 · via NIH RePORTER
Clinical research
18 studies
Active
3 studies- PIA5432: Optimizing Implementation of Long-Acting ART and Implementation Research (LATIR) in the ACTG through Qualitative Research with A5359 Trial Participants and Study StaffNational Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2026)
- PIA5321:Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) StudyNational Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2025)
- PIThe Role of Sleep in Cardiovascular Health Among Men Living with HIVRutgers, The State University of New Jersey · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (15)
- PINCT05551273Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2026)Hepatitis B; HIV Infections
- PINCT06694805A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)PHASE3 · VIIV Healthcare · CLOSED TO ACCRUAL (as of 2026)HIV Infections
- PIA Proposal to Cure HCV And Guide Engagement among People Living with HIV (CHANGE)Columbia University Medical Center · IRB STUDY CLOSURE (as of 2025)
- PINCT06101329A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United StatesPHASE2 · Gilead Sciences, Inc. · CLOSED TO ACCRUAL (as of 2025)Pre-Exposure Prophylaxis of HIV Infection
- PINCT04193189B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-BPHASE3 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)HIV Infection; Hepatitis B
- PINCT04840199Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical OutcomesPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)HIV Infections; Cytomegalovirus; CMV
- PINCT04042740Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)Hepatitis C Infection; HIV Infection
- PINCT04611802A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)PHASE3 · Novavax, Inc · IRB STUDY CLOSURE (as of 2023)SARS-CoV Infection; Covid19
- PINCT04470427A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and OlderPHASE3 · ModernaTX · IRB STUDY CLOSURE (as of 2023)SARS-CoV-2
- PIIndividual Patient Emergency Compassionate Use with Casirivimab and ImdevimabWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
- PICOVID-19 Prevention Network (CoVPN) ScreeningWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
- PINCT04042740Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2021)Hepatitis C Infection; HIV Infection
- PIRemdesivir (RDV; GS-5734) for the Treatment of Selected Coronavirus (CoV) InfectionGilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2021)
- PINCT04292899A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2020)COVID-19
- PINCT04292730A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care TreatmentPHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2020)COVID-19
News mentions
5 mentionsView all WCM news ↗
- Awards & Honors: December 2025December 31, 2025
Awards, honors and achievements for the month of December.
- Updated Hep B Vaccine More Effective for People with HIVDecember 11, 2024
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.
- Accessible Care Key to Treating Hepatitis C in People Who Inject DrugsApril 7, 2022
Among participants who had hepatitis C and who injected drugs, those treated at a non-stigmatizing “accessible care” treatment center co-located with a syringe service program (SSP) were nearly three times more likely to be cured of the infectious disease compared with those referred out to local clinicians through patient navigation, according to a randomized clinical trial led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, NYU Grossman School of Medicine, and the CUNY Graduate School of Public Health and Health Policy.
- Mission Possible: Weill Cornell Medicine Launches an Unprecedented Research Effort in the Battle Against COVID-19March 2, 2021
Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.
External relationships
Other
Novo Nordisk Pharmaceuticals, Inc.